drugset / Trial / NCT03531632
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of the combination of MGD007 and MGA012 will also be assessed.
Timeline
- Start
- 2018-06-04
- Primary completion
- 2020-02-08
- Completion
- 2020-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGD007 | Protein / enzyme biologic | — | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |